With the increasing incidence of respiratory diseases and allergies worldwide, the need for clinical trial expertise in these areas is essential to running a successful clinical study or a full clinical development program. A key quality that distinguishes SCOPE from our competitors is our ability to consistently provide this expertise and meet enrollment goals on time and budget. SCOPE can help develop and deliver the enrollment strategy for your respiratory or allergy clinical trial.
In business since 2000, we have conducted over 260 studies with 70,000 patients world-wide. We have offices in 16 countries across Europe, Russia, Ukraine and the USA with 250 permanent employees. With our partner network, we are operational across all continents and markets wherever clinical trial services are required. SCOPE has significant experience in conducting phase II-IV respiratory clinical trials, ranging from a single protocol to full development programs. In recent years, we have conducted more than 36 studies in the respiratory area for various disease states.
Our patient recruitment, site management and extensive support strategies are uniquely adapted to the specific therapeutic areas and clinical development stages of your product. With our expertise and experience, we can make sure your trial runs as efficiently as possible, meeting all regulatory standards while ensuring consistent quality.
Whether it’s a clinical development trial (phase I-III), post-authorization (phase IV), rescue, adaptive design study, or even a complex device or diagnostic combination design, we have the expertise, know-how, and resources to guide you smoothly through all phases of development while meeting your objectives in a timely and cost-efficient manner.